Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory...
(Source: Xencor Inc) MONROVIA, Calif., May 13, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Reports Third Quarter 2014 Financial Results Conference call today at...
, Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and...
View ArticleXencor Reports Third Quarter 2014 Financial Results (Xencor Inc)
(Source: Xencor Inc) Conference call today at 4:30 p.m. EST MONROVIA, Calif., Nov. 10, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered...
View ArticleXencor to Host R&D Day and Webcast on June 26, 2015
MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...
MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Complete Data Results from XmAb7195 Phase 1a Trial Showing...
(Source: Xencor Inc) MONROVIA, Calif., May 18, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor to Host Second Quarter 2016 Financial Results Webcast and Conference...
(Source: Xencor Inc) MONROVIA, Calif., July 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Host Analyst Day and Webcast on June 28, 2016 (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., June 14, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Host Third Quarter 2016 Financial Results Webcast and Conference...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Upcoming Investor Conferences (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor to Present at Leerink Partners 6th Annual Global Healthcare Conference...
(Source: Xencor Inc) MONROVIA, Calif., Feb. 9, 2017 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticlePreliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in...
(Source: Xencor Inc) MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment...
View ArticleXencor Initiates Phase 1b Trial of Subcutaneous Formulation of XmAb7195...
(Source: Xencor Inc) MONROVIA, Calif., Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and...
(Source: Xencor Inc) Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 Conference call...
View ArticleXencor Appoints A. Bruce Montgomery, M.D. to Board of Directors (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors
MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Initiates Two Phase 2 Trials of XmAb5871 in IgG4-Related Disease and...
MONROVIA, Calif., March 7, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune...
View ArticleXencor Appoints Yujiro S. Hata to Board of Directors (Xencor Inc)
(Source: Xencor Inc) MONROVIA, Calif., July 31, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View ArticleXencor Reports Complete Data Results on XmAb5871 Program at European League...
(Source: Xencor Inc) MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the...
View Article